GENE ONLINE|News &
Opinion
Blog

2020-11-29| Trials & Approvals

Vertex Bags EU Approval for Cystic Fibrosis Treatment in Children Aged 6-11 Years

by Daniel Ojeda
Share To

On November 27, Vertex Pharmaceuticals announced that the label extension for the combination treatment of SYMKEVI (tezacaftor/ivacaftor) with KALYDECO (ivacaftor) has been approved by the European Commission. This treatment can now be used to treat cystic fibrosis in children 6-11 years who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene, the most common mutation that leads to cystic fibrosis, or one copy of the F508del mutation and one copy of one of 14 mutations in the CFTR gene.

Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which results in the production of a dysfunctional protein. CFTR protein is necessary to attract water to the surface of cells, without which the mucus in the lungs clogs the airway and traps bacteria. As a result, patients with CF suffer from infections, inflammation, respiratory failure, and progressive lung damage that have life-shortening consequences. The average life expectancy of a person with CF is around 37.5 years.

Tezacaftor addresses the trafficking and processing defect of the CFTR protein to enable it to reach the cell surface and ivacaftor enhances the function of the protein once it reaches the cell surface.

Globally, there are more than 75,000 people living with CF, with around 35,000 of them living in the United States. Currently, CF screening is performed in newborns and can be detected within the first month of life. Approximately 1,000 new cases are diagnosed each year. Before the creation of drugs that improved the function of the CFTR protein, the only treatment options were antibiotics for lung infections, anti-inflammatory treatments to reduce the swelling on the airways, mucus-thinning drugs.

“With this approval, children with CF in Europe ages 6 to 11 years with the most common mutation, F508del, have a new treatment option and children with certain residual function mutations will, for the first time, have a treatment option available that addresses the underlying cause of their CF,” said Reshma Kewalramani, M.D., Chief Executive Officer and President at Vertex. “Today’s approval brings us closer to our ultimate goal of providing medicines for all people with CF.”

By Daniel Ojeda, Ph.D.

Related Article: An Outlook on the Evolution of Cystic Fibrosis Care

References
  1. https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-european-commission-approval-symkevir
  2. https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/
  3. https://www.cdc.gov/genomics/disease/cystic_fibrosis.htm
  4. https://www.mayoclinic.org/diseases-conditions/cystic-fibrosis/symptoms-causes/syc-20353700
  5. https://cysticfibrosisnewstoday.com/2017/05/24/living-cf-life-expectancy/#:~:text=The%20average%20life%20expectancy%20of,with%20many%20living%20much%20longer.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
The First Approved RSV Vaccine Worldwide Belongs to AstraZeneca and Sanofi
2022-11-06
Merck’s Streptococcus pneumoniae Expansion Finally Receives European Commission Approval
2022-10-24
Kite’s Yescarta Climbs Up To Treat Second-Line B-Cell Lymphomas After EC Nod
2022-10-18
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!